Insmed Incorporated
INSM · Price history
Price at last available close
$111.59
−$2.55 (-2.23%) 1M
2026-10-29
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Insmed Incorporated
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils.
How they make money
Insmed is a global biopharmaceutical company that generates revenue primarily through the commercial sale of its proprietary therapeutic products, ARIKAYCE and BRINSUPRI. The company operates by researching, developing, and commercializing first- and best-in-class therapies for patients with serious and rare diseases, utilizing a direct sales force in key markets and distribution agreements internationally.
Products & services
ARIKAYCE (amikacin liposome inhalation suspension) for the treatment of Mycobacterium avium complex (MAC) lung disease, and BRINSUPRI (brensocatib) for the treatment of non-cystic fibrosis bronchiectasis.
Brands & revenue mix
Liposomal amikacin for inhalation.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
Customer concentration
The company does not disclose specific major customers, but notes that its revenue is derived from sales to specialty pharmacies, hospitals, and distributors.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its drug products and active pharmaceutical ingredients.Source
Strengths
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
25
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
45
Weak
Financial Strength
35
Business Quality / Moat
78
Management
0
Growth Quality
90
Risk / Durability
22
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
32
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
49/100
Building Historical Record
Model Score 49/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •Material dilution — approximately 30.2% share-count growth
- •Elevated debt risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for INSM
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can INSM maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can INSM fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Does INSM's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What specifically needs to improve for INSM to reach sustainable profitability?
- •What future growth or profitability would be needed to justify INSM's current valuation?
Essential Investment Snapshot
Wall Street Score
25
Opportunity Score
32
Market Cap
$24.37B
P/E Ratio
-27.8
EPS
$-4.11
52-Week High
$212.75
52-Week Low
$90.39
Beta
0.82
Analyst Target
$196.50
Shares Outstanding
213.6M
Total Revenue
$1.14B
Total Debt
$579.9M
Dividend
No current dividend
Liquidation Value / Share
$3.55
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Building upward momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for INSM
Detected from reported data — verify before acting.Material dilution — approximately 30.2% share-count growth
Diluted shares outstanding grew ~30.2% year-over-year. Substantial dilution reduces per-share value and can signal financing stress. Wall Street Score is capped.
Elevated debt risk
Total debt is at least one year of revenue • Interest coverage is below 2x • Free cash flow is negative
Community Sentiment
0 active · 0 total callsNo personal call yet on INSM.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary liposomal technology platform.
- +Established commercial infrastructure for rare disease therapies.
Potential downside factors
- −Debt risk (elevated): Total debt is at least one year of revenue.
- −Interest coverage is below 2x.
- −Free cash flow is negative.
- −Dependence on third-party manufacturers.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
25
Aug 14, 2026
Change
Unchanged
Current Score
25
Oct 1, 2026
Category Changes
INSM score was unchanged.
Projected Score
Projected Score
23
Projected Change
-2.0 points
Preliminary comparable-period financial changes suggest decline of approximately 2.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$111.59
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: +66.7%
Revenue changed sharply from 2024 to 2025. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.14B | $606.4M | $363.7M | $305.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $192.2M | $124.9M | $85.7M | $65.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $945.4M | $481.5M | $278.0M | $239.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $860.8M | $771.1M | $598.4M | $571.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $893.6M | $701.2M | $461.1M | $344.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $1.76B | $1.66B | $1.16B | $949.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$763.8M | -$1.17B | -$818.8M | -$660.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$817.5M | -$1.18B | -$878.3M | -$709.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $81.3M | $83.8M | $84.9M | $81.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$869.1M | -$1.27B | -$910.1M | -$747.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $6.2M | $5.0M | $3.7M | $2.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$875.3M | -$1.28B | -$913.8M | -$749.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-4.11 | $-6.41 | $-5.57 | $-5.34 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 217M | 214M | 164M | 140M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 217M | 214M | 164M | 140M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$425.5M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.06
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-22.0%
Cash Change
-57.6%
Margin Change
+296.4 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Debt reduced
What Weakened
- Cash position declined
Potential Score Impact
Positive indicators included revenue growth, debt levels, net income margin. Pressure indicators included EPS growth, cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 296.1%. EPS declined 96.5%. Cash declined 57.6%. Total debt declined 22.0%. Net income margin improved by 296.4 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Insmed (INSM) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026
Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026
Rumor Mill · INSM
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial